StreetInsider.com News Articles

Form 4 Corbus Pharmaceuticals For: Sep 14 Filed by: Ben Yong

Tue, 15 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260915/27065638.html

H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)

Tue, 15 Sep 2026 07:21:27 -0400

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $35.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP).

The analyst commented: "This morning, Corbus released topline Phase 1b for CRB-913, demonstrating a mean weight loss of 5% at the 60 mg dose by 12 weeks and a tolerability profile with minimal GI and psychiatric events that was consistent with incretins. In our view, the data serve an important proof of principle for CB-1 inverse agonists: peripheral restriction of CB-1 agonism allows for sustained, meaningful weight loss while side-stepping the psychiatric effects of earlier CB-1 targeting drugs. At 12 weeks, weight

Form 8-K Corbus Pharmaceuticals For: Sep 14

Mon, 14 Sep 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260914/27055284.html

Corbus obesity drug hits 5% weight loss mark in phase 1b trial

Mon, 14 Sep 2026 07:03:09 -0400

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported topline data from its CANYON-1 Phase 1b clinical trial of CRB-913, an oral obesity treatment, showing statistically significant weight loss across all three tested doses after 12 weeks.

The double-blind, placebo-controlled study enrolled 254 obese, non-diabetic adults at 15 U.S. sites. Participants were randomized to receive 20 mg, 40 mg, or 60 mg of CRB-913 once daily, or a placebo. The 60 mg dose produced a mean weight loss of 5.0% from baseline, compared to 3.3% for the 40 mg dose and 2.8% for the 20 mg dose. The placebo group recorded no mean

Corbus obesity drug hits 5% weight loss mark in phase 1b trial

Mon, 14 Sep 2026 07:03:09 -0400

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Mon, 14 Sep 2026 07:00:00 -0400

CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed
CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile
Data support CRB-913’s potential to establish a new class of oral non-incretin obesity medicines
Data selected for late-breaking presentation at ObesityWeek® 2026
Company will hold an investor call at 8:00am EDT today

NORWOOD, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Mon, 14 Sep 2026 07:00:00 -0400

CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed
CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile
Data support CRB-913’s potential to establish a new class of oral non-incretin obesity medicines
Data selected for late-breaking presentation at ObesityWeek® 2026
Company will hold an investor call at 8:00am EDT today

NORWOOD, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

Fri, 11 Sep 2026 16:01:00 -0400

NORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.D., an investigator for the study, will be a guest speaker in the event. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

Fri, 11 Sep 2026 16:01:00 -0400

H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)

Wed, 26 Aug 2026 06:42:28 -0400

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $35.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP).

The analyst commented: "This week, Corbus, in collaboration with CSPC , published a detailed preclinical characterization of CRB-701 in Cancer Research Communications that, in our view, provides the clearest mechanistic explanation to date for why the ADC may behave differently from enfortumab vedotin (EV), despite targeting the same antigen and carrying the same MMAE payload. The differentiation starts with the construct itself. CRB-701 uses mTGase-mediated, site-specific conjugation at Q294 of each heavy chain to generate a highly homogeneous ADC with a mean

Form 4 Corbus Pharmaceuticals For: Aug 16 Filed by: Nicacio Leonardo Viana

Mon, 17 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26938354.html

Form 4 Corbus Pharmaceuticals For: Aug 16 Filed by: Nicacio Leonardo Viana

Mon, 17 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26938354.html

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 10:00:00 -0400

NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The grants were approved by the Compensation Committee of the Board of Directors effective as of August 16, 2026, as inducements material to Mr. Nicacio entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 10:00:00 -0400

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 10:00:00 -0400

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 10:00:00 -0400

Form SCHEDULE 13G/A Corbus Pharmaceuticals Filed by: CITADEL ADVISORS LLC

Fri, 14 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26930071.html

Form SCHEDULE 13G/A Corbus Pharmaceuticals Filed by: CITADEL ADVISORS LLC

Fri, 14 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26930071.html

Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Mizuho

Thu, 13 Aug 2026 06:38:09 -0400

(Updated - August 13, 2026 6:38 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $33.00 (from $34.00) while maintaining a Outperform rating.

The analyst commented: "CRBP reported 2Q results last week, for which we saw no material updates. While we lower our PT to $33 (vs. $34 prior) on minor model updates, our main focus remains progress with CRBP's two pipeline candidates, each of which has an important catalyst in September: (1) for CRB-913 (a CB1 inverse agonist for obesity), a top-line P1b CANYON-1 study data announcement; and (2) for lead asset CRB-701 (a

Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Mizuho

Thu, 13 Aug 2026 06:38:09 -0400

(Updated - August 13, 2026 6:38 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $33.00 (from $34.00) while maintaining a Outperform rating.

Form 4 Corbus Pharmaceuticals For: Aug 11 Filed by: Saxena Nishant C

Wed, 12 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26913447.html

Form 4 Corbus Pharmaceuticals For: Aug 11 Filed by: Saxena Nishant C

Wed, 12 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26913447.html

Form 4 Corbus Pharmaceuticals For: Aug 07 Filed by: Cohen Yuval

Mon, 10 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260810/26898476.html

Form 4 Corbus Pharmaceuticals For: Aug 07 Filed by: Cohen Yuval

Mon, 10 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260810/26898476.html

Form 4 Corbus Pharmaceuticals For: Aug 07 Filed by: Moran Sean F.

Mon, 10 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260810/26898460.html